1 Medical Costs, Health Care Utilization, and Productivity Losses Associated With 2 Hypertension by COVID-19 Among US Commercial Enrollees 3 4 Jun Soo Lee, PhD¹; Yidan (Xue) Zhang, PhD^{1,2}; Yu Wang, PhD^{3,4}; Joohyun Park, PhD⁵; Ashutosh Kumar, PhD^{1,6}; Bruce Donald, MA^{1,2}; Feijun Luo, PhD^{1*}; Kakoli Roy, PhD^{7*} 5 6 7 ¹ Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, 8 Atlanta, Georgia 9 ² ASRT, Inc., Atlanta, Georgia ³ Division of Workforce Development, Centers for Disease Control and Prevention, Atlanta, 10 11 Georgia ⁴ Data Science and Evaluation Team, American Heart Association, Dallas, Texas 12 ⁵ Division of Drug Overdose Prevention, Centers for Disease Control and Prevention, Atlanta, 13 14 Georgia ⁶ Bizzell US, New Carrollton, Maryland 15 ⁷ National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease 16 17 Control and Prevention, Atlanta, Georgia 18 19 20 * Feijun Luo and Kakoli Roy are co-senior authors. 21 22 23 Keywords: hypertension, productivity loss, productivity costs, medical costs, health care 24 utilization, commercial insurance, COVID-19 25 26 Word count: 3,106 27 Abstract: 321; Figures: 1; Tables: 3; eTables: 4; References: 43 28 Corresponding author: 29 Jun Soo Lee, PhD 30 Division for Heart Disease and Stroke Prevention 31 Centers for Disease Control and Prevention 32 4770 Buford Hwy, Building 107 33 Atlanta, GA 30341 34 Tel: 770-488-8978 35 Email: PQA2@cdc.gov 36 37 Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use 38 39 of trade names and commercial sources is for identification only and does not imply endorsement 40 by the US Department of Health and Human Services. 41 42 There is no potential conflict of interest related to any part of this article.

- 44 Sources of funding: The authors received no financial support for the research, authorship,
- 45 and/or publication of this article.
- 46
- 47 Acknowledgements: We thank Michael Schooley, Janet Wright, and Fátima Coronado (Centers
- 48 for Disease Control and Prevention) for their guidance, suggestions, and manuscript review. We
- 49 would like to thank Moira Urich (the Centers for Disease Control and Prevention) for review of
- 50 this manuscript.

51 Abstract

52

53 **Background:** Hypertension is a major risk factor for cardiovascular and renal diseases,

54 significantly contributing to morbidity and mortality. The COVID-19 pandemic has heightened 55 concerns about the impact of hypertension on severe COVID-19 outcomes.

56

57 Methods: We conducted a cross-sectional analysis using the 2021 MarketScan Commercial and

- 58 Health and Productivity Management databases. The study included adults aged 18-64 with
- 59 continuous employer-sponsored private insurance, excluding those with pregnancy or capitated
- 60 plans. We compared excess total medical costs, healthcare utilization (including the number of
- 61 emergency department [ED] visits, inpatient admissions, outpatient visits, and outpatient
- 62 prescription drugs), and productivity losses and related costs due to sick absences, short-term
- 63 disability (STD), and long-term disability (LTD) between individuals with and without
- 64 hypertension, further stratified by COVID-19 diagnosis. Multivariate regression models adjusted
- 65 for demographics and comorbidities were used to estimate the differences in outcomes.
- 66

67 **Results**: Among 1,612,398 adults aged 18-64 years, 13% had hypertension in 2021. Those with

68 hypertension were older, were less likely to be female or live in urban areas, and exhibited a

69 higher prevalence of comorbidities. The total excess medical costs associated with hypertension

70 were \$8723 per patient (95% CI, \$8352-\$9093), which was significantly higher by \$6117 (95%

71 CI, \$4780-\$7453) among individuals diagnosed with COVID-19. Persons with hypertension had

higher health care utilization, including a higher number of ED visits (0.21 per patient; 95% CI,

73 0.21-0.22), inpatient admissions (0.11; 95% CI, 0.10-0.12), outpatient visits (5.42; 95% CI, 5.36-

5.49), and outpatient prescription drugs (10.85; 95% CI, 10.75-10.94). Moreover, they

experienced a greater number of sick absences (1.22 days; 95% CI, 1.07-1.36) and STD

76 occurrences (3.68 days; 95% CI, 3.38-3.98) per patient compared to those without hypertension.

77 These trends were further exacerbated among individuals diagnosed with COVID-19.

78

79 **Conclusions:** Hypertension markedly increases medical costs, healthcare utilization, and

80 productivity losses, which are further exacerbated by COVID-19. These findings highlight the

81 substantial economic burden of managing hypertension in the context of the COVID-19

82 pandemic and underscore the importance of targeted interventions.

83 INTRODUCTION

Hypertension (ie, high blood pressure [BP]) is a major risk factor of cardiovascular and renal 84 diseases, which are among the leading contributors of all-cause mortality.^{1,2} Recent national 85 86 estimates indicate that approximately 122 million (47%) adults aged 20 years and older have hypertension in the United States (US).^{3,4} Moreover, hypertension has been consistently linked to 87 elevated health care utilization and increased medical cost.⁵⁻⁸ For instance, in 2019, hypertension 88 89 was implicated in over 18 million hospital discharges, with 1.4 million cases wherein hypertension was the primary diagnosis.^{3,9} The estimated medical cost associated with 90 91 hypertension was reported to be \$1500 per person per year in 2012-2013, contributing to a staggering \$109 billion (in 2015 US dollars) in total annual medical cost nationwide.⁶ 92 93 In addition to direct medical costs, hypertension is associated with productivity loss among working-age adults.¹⁰ Hypertension often goes unnoticed and remains untreated or 94 uncontrolled, indicating BP levels persistently above the recommended thresholds,¹¹ among 95 working-age adults.¹² For example, 93.4% and 74.4% of hypertensive adults in the US aged 18-96 97 44 and 45-64 years had uncontrolled hypertension, respectively, compared with 69.7% of adults aged 65 years and above.¹³ Uncontrolled hypertension is associated with comorbidities that can 98 99 lead to productivity loss. A systematic literature review of studies published from 1990 through 100 2015 suggests that hypertension-associated absenteeism, presenteeism, and short-term disability 101 cost upwards of \$60, \$70, and \$50 per person per year, respectively, resulting in billions of dollars in total annual productivity loss nationwide (eg, \$11 billion from absenteeism alone).^{10,14-} 102 16 103

In parallel, emerging evidence following the onset of the COVID-19 pandemic has
 pointed to greater morbidity and mortality among COVID-19 patients with comorbid

hypertension.¹⁷⁻¹⁹ However, research also indicates that hypertension may independently affect 106 107 COVID-19 prognosis through heightened immunological activity and organ damage, primarily in those with uncontrolled systolic BP.^{20,21} Compared with peers without hypertension, COVID-108 109 19 patients with hypertension are significantly more likely to be hospitalized and require treatment in the intensive care unit.^{17,18} Also, COVID-19 infections may lead to the onset of 110 111 hypertension in people without preexisting hypertension.²² 112 Despite this growing body of evidence, a significant gap remains in understanding the interaction between hypertension and COVID-19,²³⁻²⁵ especially regarding the impact on medical 113 costs, health care utilization, and productivity losses.²⁶⁻²⁹ To bridge this gap, our study aims to 114 115 investigate the economic burden of hypertension during the COVID-19 pandemic, specifically 116 focusing on medical costs, health care utilization, and productivity losses among employed 117 adults aged 18-64 years with employer-sponsored private insurance. Additionally, the study 118 seeks to delineate variations in hypertension-related medical costs and productivity losses based 119 on COVID-19 diagnosis status. By addressing these gaps, our study may elucidate the 120 intertwined effects of COVID-19 and hypertension on total medical costs, health care utilization, 121 and productivity loss.

123 METHODS

124 Data

125 We used the MarketScan Commercial and Health and Productivity Management (HPM) 126 databases from 2021.³⁰ The MarketScan Commercial Database contained person-level paid 127 claims and encounters, including medical costs (patients' out-of-pocket costs and insurance 128 payments) and information on health care utilization, such as inpatient services, outpatient 129 services, emergency department (ED) visits, and outpatient prescription drug claims. The data 130 came from approximately 350 payers, encompassing over 20 billion service records provided by >300 employers, >30 health plans, and >500 hospitals nationwide.³⁰ The HPM Database 131 132 contained detailed payroll-related information about employees, including sick absences, short-133 term disability (STD), and long-term disability (LTD). All data were de-identified, and the study 134 was exempt from review by the Institutional Review Board of the Centers for Disease Control 135 and Prevention.

136

137 Identification of Patients With Hypertension

138 Our sample included employed individuals aged 18-64 years who were continuously enrolled in 139 an employer-sponsored insurance plan throughout 2021. The sample excluded individuals with a 140 pregnancy diagnosis (codes listed in eTable 1) or with capitated insurance in 2021. Finally, we 141 limited the analytic sample to individuals in the HPM Database, who had complete information 142 on absences, STD, or LTD in 2021. Because not all employers provided payroll information, we 143 stratified the sample by individuals with medical cost, sick absence, and STD or LTD 144 information. In each stratified subsample, we identified individuals with hypertension if they had 145 at least 1 inpatient or ED visit or 2 outpatient visits containing a hypertension diagnosis

(International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] I10
through I15) in 2021 (eTable 1).

148

149 *Outcome Variables*

150 The primary outcome variables, measured in per person per year, are (1) total medical costs (sum

151 of patients' out-of-pocket costs and insurance payments), (2) health care utilization, including the

152 number of ED visits, inpatient admissions, outpatient visits, and outpatient prescription drugs, (3)

total missed workdays related to sick absences, STDs, and LTDs, and (4) productivity costs

154 calculated on total missed 8-hour workdays due to sick absences, STDs, and LTDs in 2021.

155 Estimated employer productivity costs were computed by multiplying the number of hours

absent from the number of missed workdays times 8 hours, with the average hourly wage in

157 2021.³¹ We adjusted for absences associated with STD (70% of hourly wage) and LTD (60% of

158 hourly wage).^{31,32} The average hourly wage (\$30.61) for all employees in private nonfarm

159 payrolls was obtained from the 2021 US Bureau of Labor Statistics (BLS).³³

160

161 Independent Variable

162 The primary independent variable is a binary variable indicating whether individuals had

163 hypertension in 2021. We interacted this variable with a binary indicator for COVID-19

164 diagnosis (individuals with ICD-10-CM of U07.1 in 2021) to examine the interaction between

165 hypertension and COVID-19 with respect to the outcome variables.

166

167 Control Variables

168	All models were adjusted for age groups (aged 18-34 [reference], 35-44, 45-54, and 55-64
169	years), sex (female [reference], male), residency (rural [reference] and urban), ³⁴ census region
170	(Northeast [reference], Midwest, South, and West), and comorbidities. Comorbidities were
171	defined using 17 conditions outlined in the Quan Charlson Comorbidities. ³⁵ Each comorbidity
172	was identified if individuals had ≥ 1 inpatient admission or ≥ 2 outpatient encounters (≥ 30 days
173	apart) using the ICD-10-CM diagnosis codes as specified in Quan et al. ³⁵

174

175 Statistical Analysis

We first documented summary statistics of patients' characteristics, including age, sex, ruralurban residence, census region, and comorbidities. We tested the differences in average values
by hypertension diagnosis status using the Wilcoxon rank-sum test for continuous variables and
Pearson's chi-square test for categorical variables.

180 In the regression analyses, where the dependent variables were total medical costs and 181 productivity costs (related to sick absences, STD, and LTD), we used a generalized linear model 182 (GLM) with a log-link function and gamma distribution. For dependent variables that were count 183 variables, specifically outcomes related to health care utilization (including the number of ED 184 visits, inpatient admissions, and outpatient prescription drugs) and missed workdays (due to sick 185 absences, STD, and LTD), a negative binomial regression model was used. We ran separate 186 regressions for each dependent variable to estimate the association with hypertension status (with 187 and without hypertension) as well as the association including the interaction of hypertension 188 status and COVID-19 diagnosis (with and without COVID-19). The remaining control variables 189 were the same for all models. We reported the predicted outcomes variables in terms of average 190 marginal effects (AMEs) for individuals, both with and without hypertension, and for those with

191 and without COVID-19. Furthermore, we documented the differences in the estimated AMEs by 192 combined hypertension status and by COVID-19 diagnosis status. AMEs represent the change in 193 the predicted outcome variables associated with a one-unit change in the independent variable, 194 holding all other variables constant. AMEs provide estimates of the predicted changes in 195 outcomes resulting from variations in hypertension and COVID-19 diagnosis. We defined the 196 differences in AMEs associated with hypertension and COVID-19 diagnosis status as "excess" 197 outcomes associated with hypertension and COVID-19. 198 In the sensitivity analysis, we applied a zero-inflated negative binomial regression model 199 for the count variables—specifically missed workdays attributable to sick absences, STD, and 200 LTD—and a two-part model for productivity costs due to potential excess zero values in the 201 dependent variables. In the two-part model, we first used a logistic regression to estimate the 202 probability of non-zero expenditures, followed by GLM regression with log-link in the second 203 part. 204 All analyses used 2021 data, which was the most recently available data. Also, there 205 might have been interruptions to medical care during the early COVID-19 pandemic in 2020,^{36,37} 206 as the severity of COVID-19 and its relationship with hypertension might have been different 207 during the early and middle stages of the pandemic. To test this potential interruption, we 208 conducted additional sensitivity analyses using 2020 data. The sensitivity analysis results using 209 2020 were adjusted to 2021 dollars using the Consumer Price Index from the US BLS.³⁸

Two-tailed tests with *P* values of <0.05 were used to indicate statistical significance. All analyses were conducted using Stata SE version 17 (StataCorp, College Station, Texas).

212

213 **RESULTS**

214	We identified 1 612 398 employed individuals aged 18-64 years who were continuously enrolled
215	in a noncapitated employer-sponsored private insurance plan without a pregnancy history in
216	2021 (Figure 1). Among these individuals, 139 490 (9%) had non-missing information on
217	workplace absences, 1 355 064 (84%) had non-missing information on STD, and 1 331 963
218	(83%) had non-missing information on LTD. A total of 215 480 (13%) individuals had
219	hypertension in 2021. Persons with hypertension were older (51.2 vs 42.9 years; $P < 0.001$), were
220	less likely to be female (34.0% vs 39.4%; $P < 0.001$), were less likely to reside in urban areas
221	(90.4% vs 92.7%; $P < 0.001$), and had a higher likelihood of having comorbidities ($P < 0.001$ in
222	all comorbidities) (Table 1).
223	Table 2 presents the total adjusted medical costs and health care utilization associated
224	with hypertension, including by COVID-19 diagnosis. The mean total excess medical costs
225	associated with hypertension compared to those without hypertension were \$8723 per patient per
226	year (95% CI, \$8352-\$9093; $P < 0.001$). The total excess medical costs associated with
227	hypertension were significantly higher among persons with COVID-19 than those without
228	COVID-19 (\$14 290 vs \$8173; the difference was \$6117 [95% CI, \$4780-\$7453; <i>P</i> < 0.001]).
229	Individuals with hypertension had a higher number of ED visits (0.211 per patient; 95% CI,
230	0.207-0.216; P < 0.001), inpatient admissions (0.108; 95% CI, 0.101-0.115; P < 0.001),
231	outpatient visits (5.422; 95% CI, 5.357-5.486; $P < 0.001$), and outpatient prescription drugs
232	(10.85; 95% CI, 10.75-10.94; $P < 0.001$) than those without hypertension (Table 2). Compared
233	with adults without COVID-19 diagnosis, those with COVID-19 had a significantly higher
234	number of excess ED visits (0.128; 95% CI, 0.105-0.151; <i>P</i> < 0.001), inpatient admission (0.293;
235	95% CI, 0.259-0.328; <i>P</i> < 0.001), and outpatient prescription drugs (0.452; 95% CI, 0.132-0.772;
236	P < 0.001) associated with hypertension compared to those without hypertension (Table 2).

237	Table 3 documents the productivity losses and costs associated with hypertension by
238	COVID-19 diagnosis. Individuals with hypertension had a higher number of sick absences
239	(1.215 days per patient; 95% CI, 1.068-1.362; P < 0.001), STD (3.680; 95% CI, 3.381-3.980;
240	<i>P</i> <0.001), and higher sick absence costs (\$297.3 per patient; 95% CI, \$254.1-\$340.6; <i>P</i> <0.001)
241	and STD costs (\$631.0; 95% CI, \$591.4-\$670.7; P < 0.001). Compared with persons without
242	COVID-19 diagnosis, those with COVID-19 had a significantly higher number of excess STD
243	(2.412; 95% CI, 0.837-3.987; <i>P</i> < 0.01) and STD costs (\$413.6; 95% CI, \$205.0-\$622.2;
244	P < 0.001) associated with hypertension.
245	The sensitivity analyses using a zero-inflated negative binomial and a two-part model are
246	presented in eTable 2. The magnitudes and directions were similar to results from the main
247	analyses, except the number and costs of LTD by COVID-19 diagnosis status became
248	statistically significant.
249	eTables 3 and 4 presented the same results as Tables 2 and 3 using 2020 data. The total
250	medical costs associated with hypertension were \$8961 (95% CI, \$8478-\$9445; $P < 0.001$) in
251	2020 (eTable 3), very similar to the 2021 estimate of \$8723 using 2021 data (Table 2). On the
252	other hand, the differences in total excess medical costs associated with hypertension by
253	COVID-19 diagnosis status were much higher in 2020 estimates (\$18167; 95% CI, \$14320-
254	\$22014; <i>P</i> < 0.001) than 2021 estimates (\$6117; 95% CI, 4780-7453) (Table 2). The differences
255	in excess inpatient admission associated with hypertension by COVID-19 diagnosis status were
256	0.986 per patient (95% CI, 0.825-1.147; $P < 0.001$) (eTable 3), more than 3 times higher than the
257	0.293 estimate using 2021 data (Table 2). Similarly, the differences in the number of excess ED
258	

- differences of excess productivity losses, and costs associated with hypertension by COVID-19
 diagnosis in 2020 (eTable 4), were similar to estimates in 2021.
- 261

262 **DISCUSSION**

- 263 This is the first study to assess the excess medical costs, health care utilization, and productivity-
- related outcomes and costs associated with hypertension by COVID-19 diagnosis. In 2021,
- adults aged 18-64 years with employer-sponsored private insurance experienced an estimated
- excess medical cost of \$8723 per patient associated with hypertension. Meanwhile, the combined
- 267 productivity loss attributable to hypertension resulting from sick absences and STD was \$928 per
- 268 patient. Furthermore, patients with hypertension who had a COVID-19 diagnosis exhibited
- significantly higher medical costs compared to those without COVID-19. Overall, the excess
- 270 medical cost associated with hypertension was \$6117 higher for individuals with a COVID-19
- diagnosis in comparison to those without a COVID-19 diagnosis. Furthermore, a COVID-19
- diagnosis was associated with a \$414 increase in hypertension-associated excess STD-related
- 273 costs, whereas sick absences and LTD-related productivity losses were not significantly different
- for persons with and without COVID-19. The higher medical cost associated with hypertension
- among patients with a COVID-19 diagnosis was primarily driven by increased ED visits,
- inpatient admissions, and outpatient prescription drugs.

Given the interdependent relationship between hypertension and COVID-19 in our regression models, our findings can also be interpreted as excess costs, utilization and productivity losses associated with COVID-19 diagnosis among individuals with and without hypertension. For instance, total medical costs associated with COVID-19 can be interpreted as being significantly higher among persons with hypertension compared to those without.

Similarly, other health care utilization and productivity outcomes indicated considerably higher
 associations with COVID-19 diagnosis among individuals with hypertension compared to those
 without.

285 Our findings are consistent with prior research, indicating elevated number of ED visits, 286 inpatient and outpatient treatment, and medication use among adults with hypertension compared to those without.^{5,6} However, our estimated medical cost associated with hypertension (\$8723) 287 288 per patient per year) significantly surpasses prepandemic estimates derived from national 289 household surveys, which were typically \$1500-\$2500 per person annually.⁵⁻⁷ Several factors 290 may underlie these discrepancies. First, the focus of our study on the COVID-19 period may 291 inherently differ from prepandemic studies, in terms of health care utilization and medical costs. 292 Second, our study may differ from prior research that encompassed individuals across various 293 insurance types. This difference may explain variations in costs between privately insured 294 employed adults in our study, and previous studies' populations, which likely also included those 295 covered by public insurance as well as uninsured population. Third, previous studies using 296 survey data identified individuals with lifetime hypertension, whereas our analysis, based on 297 claims databases, focused on individuals diagnosed with hypertension within the study year. 298 Adults with documented lifetime hypertension in survey databases may have received ongoing 299 management and control for their condition, potentially resulting in lower recorded hypertension-300 related medical costs compared to those diagnosed within our study sample. And fourth, our 301 stringent criteria for identifying individuals with hypertension—requiring them to have at least 1 302 inpatient admission or 2 outpatient visits with a hypertension diagnosis—might have 303 inadvertently excluded individuals with less severe hypertension.

304	Preexisting hypertension may increase the risk of severe COVID-19 symptoms; likewise,
305	COVID-19 may be associated with subsequent onset or exacerbation of hypertension. ^{20-22,39} For
306	example, existing evidence has linked hypertension with increased hyperinflammatory responses
307	following a SARS-CoV-19 infection, which may contribute to a more severe trajectory of
308	COVID-19.20 In a study involving more than 5500 inpatients with COVID-19 who had no
309	history of hypertension, 21% developed new-onset hypertension during hospitalization. ²² The
310	potential correlation between hypertension and more severe COVID-19 symptoms may in part
311	explain our findings that hypertension-related health care utilization and costs are higher among
312	persons with a COVID-19 diagnosis. ^{24,40}
313	Also, in our sensitivity analysis, we observed significantly higher medical costs associated
314	with hypertension among those diagnosed with COVID-19 in 2020 compared to 2021. The
315	introduction of mRNA-based COVID-19 vaccines, proven safe and effective for individuals with
316	hypertension, ⁴¹ might have played a role in the reduction of hypertension-related medical costs in
317	2021 vs 2020. ⁴² Further exploration may be required to understand the temporal impact of
318	vaccination on hypertension disease severity and medical costs. Understanding the evolving
319	dynamics between COVID-19 disease management, vaccination programs, and associated
320	medical costs-especially among those with poor baseline health and/or comorbidities like
321	hypertension-may help assess the broader implications of COVID-19 interventions on health
322	care costs and outcomes.
323	Lastly, prior research has consistently demonstrated the substantial impact of hypertension
324	on productivity, contributing to increased work absences, compromised on-the-job productivity,
325	and heightened disabilities. ¹⁰ Our study further contributes to this literature by unveiling the
326	compounded effect of a COVID-19 diagnosis on productivity losses associated with

327	hypertension. This finding illuminates the intricate interplay between COVID-19 and
328	hypertension, encouraging a reevaluation of the broader economic repercussions of the
329	pandemic. In this context, it becomes crucial for future investigations to not only account for the
330	direct medical and productivity costs linked to COVID-19 treatment but also to consider the
331	additional economic burden in managing concurrent chronic conditions such as hypertension.
332	Understanding and addressing these intertwined health care challenges are pivotal for devising
333	comprehensive strategies aimed at mitigating the multidimensional impacts of global health
334	crises, exemplified by the ongoing challenges posed by COVID-19.
335	

336 Limitation

337 This study is subject to several limitations. First, the MarketScan Commercial Database, 338 sourced from large employers, represents a convenience sample, limiting the generalizability of 339 findings to privately insured individuals with payroll information. Consequently, the study 340 findings cannot be generalized to the broader spectrum of privately insured US adults. Second, 341 the findings might not accurately represent individuals lacking health insurance or covered by 342 public insurance programs like Medicare and Medicaid. Notably, one of our primary outcomes— 343 productivity losses—is contingent upon data from employers' payroll systems, thereby excluding 344 persons without employment or those covered by public insurance. Third, our study focused 345 solely on surviving individuals with hypertension and COVID-19, precluding the assessment of 346 costs and productivity due to mortality. Fourth, we were unable to ascertain the severity levels of 347 hypertension and COVID-19, which could have distinct effects on the outcomes, potentially 348 leading to an underestimation of our results. Lastly, while emerging evidence links hypertension with an elevated risk of Long COVID symptoms,⁴³ our cross-sectional data precluded an 349

evaluation of the longitudinal impact of a COVID-19 diagnosis on hypertension-related healthcare utilization and economic costs.

352

353 CONCLUSIONS

- 354 The economic burden of hypertension, in terms of medical costs and productivity loss, is
- 355 substantial. Our study reveals that individuals diagnosed with COVID-19 incurred even higher
- 356 excess medical costs, health care utilization, and productivity losses attributable to hypertension.
- 357 These findings emphasize the importance of factoring in costs of chronic comorbidities in
- assessing the overall economic burden of COVID-19. These estimates can help assess the
- 359 economic impact (eg, costs averted) of interventions effective in preventing COVID-19 among
- 360 individuals with preexisting hypertension.

REFERENCES

1. Aune D, Huang W, Nie J, Wang Y. Hypertension and the risk of all-cause and causespecific mortality: an outcome-wide association study of 67 causes of death in the National Health Interview Survey. *BioMed Research International*. 2021;2021

2. Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. *NCHS Data Brief*. Dec 2022;(456):1-8.

3. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. *Circulation*. 2023;147(8):e93-e621. doi:doi:10.1161/CIR.00000000001123

4. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). Data from: National Health and Nutrition Examination Survey Data, 2017-2020. 2020. *Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.*

5. Kirkland EB, Heincelman M, Bishu KG, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. *Journal of the American Heart Association*. 2018;7(11):e008731.

6. Zhang D, Wang G, Zhang P, Fang J, Ayala C. Medical expenditures associated with hypertension in the US, 2000–2013. *American journal of preventive medicine*. 2017;53(6):S164-S171.

7. Wang G, Zhou X, Zhuo X, Zhang P. Annual total medical expenditures associated with hypertension by diabetes status in US adults. *American journal of preventive medicine*. 2017;53(6):S182-S189.

8. Mitchell EM. Concentration of healthcare expenditures and selected characteristics of persons with high expenses, U.S. Civilian Noninstitutionalized Population, 2020. *Statistical Brief (Medical Expenditure Panel Survey (US))*. Agency for Healthcare Research and Quality (US); 2023.

9. Data from: HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2019. *Agency for Healthcare Research and Quality, Rockville, MD*.

10. MacLeod KE, Ye Z, Donald B, Wang G. A literature review of productivity loss associated with hypertension in the United States. *Population Health Management*. 2022;25(3):297-308.

11. Whelton PK, Carey RM, Aronow WS, et al. 2017

ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248.

12. Wall HK, Hannan JA, Wright JS. Patients with undiagnosed hypertension: hiding in plain sight. *JAMA*. 2014;312(19):1973-1974. doi:10.1001/jama.2014.15388

13. Centers for Disease Control and Prevention (CDC). Division of Heart Disease and Stroke Prevention. Estimated Hypertension Prevalence, Treatment, and Control Among U.S. Adults. Accessed November 1, 2023. <u>https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html</u>

14. Henke RM, Carls GS, Short ME, et al. The relationship between health risks and health and productivity costs among employees at Pepsi Bottling Group. *Journal of occupational and environmental medicine*. 2010:519-527.

15. Kowlessar NM, Goetzel RZ, Carls GS, Tabrizi MJ, Guindon A. The relationship between 11 health risks and medical and productivity costs for a large employer. *Journal of occupational and environmental medicine*. 2011:468-477.

16. Kirkham HS, Clark BL, Bolas CA, et al. Which modifiable health risks are associated with changes in productivity costs? *Population Health Management*. 2015;18(1):30-38.

17. Ebinger JE, Driver M, Joung S, et al. Hypertension and excess risk for severe COVID-19 illness despite booster vaccination. *Hypertension*. 2022;79(10):e132-e134.

18. Chen J, Liu Y, Qin J, et al. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study. *Postgraduate medical journal*. 2022;98(1161):515-522.

19. World Health Organization. (2021). Hypertension and COVID-19: scientific brief, 17 June 2021. World Health Organization.

https://iris.who.int/bitstream/handle/10665/341848/WHO-2019-nCoV-Sci-Brief-Hypertension-2021.1-eng.pdf.

20. Trump S, Lukassen S, Anker MS, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. *Nature biotechnology*. 2021;39(6):705-716.

21. Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: Current evidence and perspectives. *High Blood Pressure & Cardiovascular Prevention*. 2022;29(2):115-123.

22. Zhang V, Fisher M, Hou W, Zhang L, Duong TQ. Incidence of New-Onset Hypertension Post–COVID-19: Comparison With Influenza. *Hypertension*. 2023;80(10):2135-2148. doi:doi:10.1161/HYPERTENSIONAHA.123.21174

23. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. *Nutrition, Metabolism and Cardiovascular Diseases*. 2021;31(3):745-755.

24. Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. *Journal of cardiovascular pharmacology*. 2021;78(5):e648.

25. Batiha GE-S, Gari A, Elshony N, et al. Hypertension and its management in COVID-19 patients: The assorted view. *International Journal of Cardiology Cardiovascular Risk and Prevention*. 2021;11:200121.

26. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. *Annals of Internal Medicine*. 2021/04/20 2020;174(4):576-578. doi:10.7326/M20-5661

27. Ohsfeldt RL, Choong CK-C, Mc Collam PL, Abedtash H, Kelton KA, Burge R. Inpatient Hospital Costs for COVID-19 Patients in the United States. *Advances in Therapy*. 2021/11/01 2021;38(11):5557-5595. doi:10.1007/s12325-021-01887-4

28. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *Journal of Medical Economics*. 2021/01/01 2021;24(1):308-317. doi:10.1080/13696998.2021.1886109

29. Lee JS, Lowe Beasley K, Schooley MW, Luo F. Trends and Costs of US Telehealth Use Among Patients With Cardiovascular Disease Before and During the COVID-19 Pandemic. *Journal of the American Heart Association*. 2023;12(4):e028713.

30. Data from: Truven Health MarketScan® Research Databases.

https://marketscan.truvenhealth.com/marketscanportal Accessed March 9, 2023.

31. Park J, Bigman E, Zhang P. Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18–64 Years With Large Employer-Sponsored Insurance. *Diabetes care*. 2022;45(11):2553-2560.

32. Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. *Annals of Allergy, Asthma & Immunology*. 2019;123(6):564-572. e3.

33. U.S. Bureau of Labor Statistics, Average Hourly Earnings of All Employees, Total Private [CES050000003], retrieved from FRED, Federal Reserve Bank of St. Louis; https://fred.stlouisfed.org/series/CES050000003, October 3, 2023.

34. Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. US Department of Health and Human Services, Centers for Disease Control and ...; 2014.

35. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical care*. 2005:1130-1139.

36. Papautsky EL, Rice DR, Ghoneima H, et al. Characterizing health care delays and interruptions in the United States during the COVID-19 pandemic: internet-based, cross-sectional survey study. *Journal of medical Internet research*. 2021;23(5):e25446.

37. Czeisler MÉ, Marynak K, Clarke KE, et al. Delay or avoidance of medical care because of COVID-19–related concerns—United States, June 2020. *Morbidity and mortality weekly report*. 2020;69(36):1250.

38. U.S. Bureau of Labor Statistics, Consumer Price Index for All Urban Consumers: All Items in U.S. City Average [CPIAUCSL], retrieved from FRED, Federal Reserve Bank of St. Louis; <u>https://fred.stlouisfed.org/series/CPIAUCSL</u>, October 3, 2023.


39. Delalić Đ, Jug J, Prkačin I. ARTERIAL HYPERTENSION FOLLOWING COVID-19: A RETROSPECTIVE STUDY OF PATIENTS []] NA CENTRAL EUROPEAN TERTIARY CARE CENTER. Acta Clin Croat. Jun 2022;61(Suppl 1):23-27. doi:10.20471/acc.2022.61.s1.03

40. Scott A, Ansari W, Khan F, et al. Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19. *BMC Medicine*. 2024/02/01 2024;22(1):46. doi:10.1186/s12916-023-03234-6

41. Shibata S, Kobayashi K, Tanaka M, et al. COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19.

Hypertension Research. 2023/03/01 2023;46(3):589-600. doi:10.1038/s41440-022-01134-5
42. Centers for Disease Control and Prevention (CDC). CDC Museum COVID-19 Timeline.
Accessed November 1, 2023. https://www.cdc.gov/museum/timeline/covid19.html

43. Song Z, Giuriato M. Demographic And Clinical Factors Associated With Long COVID: Study examines demographic and clinical factors associated with long COVID among people who suffer symptoms long after they were first diagnosed with COVID-19 (long haulers). *Health Affairs*. 2023;42(3):433-442.



Abbreviations: HPM, Health and Productivity Management; LTD, long-term disability; STD, short-term disability.

43 **Table 1.** Summary Statistics, MarketScan® Commercial Insurance, 2021^a

	All	Without	With hypertension
		hypertension	
	N = 1 612 398	N = 1 396 918	N = 215480
Age, mean (SD)	44.0 (11.1)	42.9 (11.0)	51.2 (8.5)***
Age groups, n (%)			
18-34	394 617 (24.47%)	383 744 (27.47%)	10873 (5.05%)***
35-44	411 201 (25.50%)	376 307 (26.94%)	34 894 (16.19%)***
45-54	451 159 (27.98%)	372 585 (26.67%)	78 574 (36.46%)***
55-64	355 421 (22.04%)	264 282 (18.92%)	91 139 (42.30%)***
Female, n (%)	623 335 (38.66%)	550 081 (39.38%)	73 254 (34.00%)***
Urban residency, n (%)		1 294 879	
• • • • •	1 489 709 (92.39%)	(92.70%)	194 830 (90.42%)***
Census regions, n (%)			
Northeast	239 802 (14.87%)	211 483 (15.14%)	28 319 (13.14%)***
Midwest	387 301 (24.02%)	334 612 (23.95%)	52 689 (24.45%)***
South	694 461 (43.07%)	585 403 (41.91%)	109 058 (50.61%)***
West	283 790 (17.60%)	259 426 (18.57%)	24 364 (11.31%) ^{***}
COVID-19 diagnosis, n (%)	144 896 (8.99%)	118940 (8.51%)	25 956 (12.05%)***
Comorbidities, n (%)			
Myocardial infarction	8 243 (0.51%)	2 901 (0.21%)	5342 (2.48%)***
Congestive heart failure	8648 (0.54%)	2378 (0.17%)	6270 (2.91%)***
Peripheral vascular disease	7538 (0.47%)	2959 (0.21%)	4579 (2.13%)***
Cerebrovascular disease	2538 (0.16%)	944 (0.07%)	1594 (0.74%)***
Dementia	119 (0.01%)	56 (0.00%)	$63 (0.03\%)^{***}$
Chronic pulmonary disease	36 105 (2.24%)	24 416 (1.75%)	11 689 (5.42%)***
Rheumatic disease	9912 (0.61%)	7154 (0.51%)	2758 (1.28%)***
Peptic ulcer disease	1322 (0.08%)	767 (0.05%)	555 (0.26%)***
Mild liver disease	14064 (0.87%)	8241 (0.59%)	5823 (2.70%)***
Diabetes without chronic			
complication	91 093 (5.65%)	41 273 (2.95%)	49 820 (23.12%)***
Diabetes with chronic			
complication	18 362 (1.14%)	6706 (0.48%)	11 656 (5.41%)***
Hemiplegia or paraplegia	1284 (0.08%)	554 (0.04%)	730 (0.34%)***
Renal disease	10 807 (0.67%)	2459 (0.18%)	8348 (3.87%)***
Any malignancy	25 244 (1.57%)	17 617 (1.26%)	7627 (3.54%)***
Moderate or severe liver			(111)
disease	767 (0.05%)	372 (0.03%)	395 (0.18%)***
Metastatic solid tumor	3396 (0.21%)	2212 (0.16%)	1184 (0.55%)***
AIDS/HIV	3447 (0.21%)	2527 (0.18%)	920 (0.43%)***

44

45 Abbreviations: SD, standard deviation.

^aWe used the Wilcoxon nonparametric rank-sum test to test the differences in means for continuous variables, and

47 the Pearson's chi-square test to test differences in proportions for categorical variables by medication nonadherence

48 to antihypertensive drug status. *** P < 0.001

49 **Table 2.** Total Medical Costs and Health Care Utilization Associated With Hypertension, 2021^a

	All	Without COVID-	With COVID-19	With COVID-19 vs
Total medical costs, \$		19 diagnosis	diagnosis	without COVID-19
Without hypertension	0056	0000	17.446	0010***
without hypertension	9056	8228	17 446	9219***
With hyportonsion	(8724 to 9387)	(7945 to 8510)	(16518 to 18374)	(8519 to 9918)
With hypertension	17 779	16401	31736	15 335***
Difference ^b	(17 131 to 18 426)	(15 830 to 16 971)	(29 801 to 33 671)	(13718 to 16952)
Difference	8723*** (8252 to 0002)	8173*** (7921 to 9515)	14 290***	6117*** (4780 to 7452)
Observations	(8352 to 9093) 1 612 398	(7831 to 8515)	(12 888 to 15 691)	(4780 to 7453)
Health care utilization	1012398	1 467 502	144 896	1 612 398
Number of emergency department visits				
Without hypertension	0.176	0.148	0.461	0.313***
	(0.175 to 0.177)	(0.147 to 0.149)	(0.454 to 0.468)	(0.306 to 0.320)
With hypertension	0.388	0.348	0.789	0.441***
	(0.383 to 0.392)	(0.344 to 0.352)	(0.767 to 0.811)	(0.419 to 0.463)
Difference ^b	0.211***	0.200***	0.328***	0.128***
	(0.207 to 0.216)	(0.195 to 0.204)	(0.305 to 0.351)	(0.105 to 0.151)
Observations	1 612 398	1 467 502	144 896	1 612 398
Number of inpatient admissions		1107002	111070	
Without hypertension	0.0476	0.0297	0.229	0.199***
* *	(0.0443 to			
	0.0508)	(0.0280 to 0.0313)	(0.208 to 0.249)	(0.180 to 0.218)
With hypertension	0.156	0.111	0.604	0.492***
	(0.146 to 0.165)	(0.105 to 0.117)	(0.549 to 0.658)	(0.442 to 0.542)
Difference ^b	0.108***	0.0817***	0.375***	0.293***
	(0.101 to 0.115)	(0.0772 to 0.0861)	(0.337 to 0.413)	(0.259 to 0.328)
Observations	1 612 398	1 467 502	144 896	1 612 398
Number of outpatient visits				
Without hypertension	8.522	8.223	11.55	3.329***
	(8.505 to 8.539)	(8.207 to 8.240)	(11.48 to 11.62)	(3.260 to 3.399)
With hypertension	13.94	13.66	16.81	3.151***
	(13.88 to 14.01)	(13.60 to 13.73)	(16.61 to 17.02)	(2.937 to 3.365)
Difference ^b	5.422***	5.438***	5.260***	-0.178
01	(5.357 to 5.486)	(5.370 to 5.505)	(5.043 to 5.477)	(-0.402 to 0.0467)
Observations	1 612 398	1 467 502	144 896	1 612 398
Number of outpatient prescription drugs				
Without hypertension	9.824	9.596	12.13	2.536***
****	(9.802 to 9.845)	(9.574 to 9.617)	(12.05 to 12.21)	(2.459 to 2.613)
With hypertension	20.67	20.40	23.39	2.988***
The second secon	(20.58 to 20.76)	(20.31 to 20.50)	(23.09 to 23.69)	(2.677 to 3.299)
Difference ^b	10.85***	10.81***	11.26***	0.452**
01	(10.75 to 10.94)	(10.71 to 10.91)	(10.95 to 11.57)	(0.132 to 0.772)
Observations	1 612 398	1 467 502	144 896	1 612 398

*** P < 0.001, ** P < 0.01, * P < 0.05.

^a We used a generalized linear model for total medical costs and a negative binomial model for the number of

52 53 54 55 emergency department visits, inpatient admissions, outpatient visits, and outpatient prescription drugs. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities.

56 57

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

	All	Without COVID- 19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Sick Absences (days)				
Without hypertension	2.181	1.990	3.870	1.880***
	(2.137 to 2.225)	(1.950 to 2.031)	(3.658 to 4.081)	(1.668 to 2.091)
With hypertension	3.396	3.220	4.952	1.732***
	(3.255 to 3.536)	(3.078 to 3.361)	(4.426 to 5.478)	(1.193 to 2.270)
Difference ^b	1.215***	1.230***	1.082***	-0.148
	(1.068 to 1.362)	(1.083 to 1.377)	(0.514 to 1.650)	(-0.727 to 0.431)
Observations	139 490	125 345	14 145	139 490
STD (days)				
Without hypertension	2.736	2.349	6.699	4.351***
	(2.628 to 2.844)	(2.262 to 2.435)	(6.212 to 7.186)	(3.903 to 4.799)
With hypertension	6.416	5.815	12.58	6.763***
	(6.082 to 6.750)	(5.506 to 6.123)	(10.99 to 14.16)	(5.195 to 8.331)
Difference ^b	3.680***	3.466***	5.878***	2.412**
	(3.381 to 3.980)	(3.184 to 3.748)	(4.312 to 7.444)	(0.837 to 3.987)
Observations	1 355 064	1 234 579	120 485	1 355 064
LTD (days)	1000 001	1201077	120.00	1000 001
Without hypertension	0.842	0.703	2.236	1.533
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(-1.676 to 3.361)	(-1.330 to 2.736)	(-5.617 to 10.09)	(-4.508 to 7.574)
With hypertension	2.470	1.996	7.216	5.220
71	(-4.927 to 9.866)	(-3.764 to 7.757)	(-18.31 to 32.75)	(-15.26 to 25.70)
Difference ^b	1.627	1.293	4.980	3.687
	(-3.268 to 6.522)	(-2.449 to 5.034)	(-12.93 to 22.89)	(-11.04 to 18.41)
Observations	1 331 963	1 211 127	120 836	1 331 963
Productivity associated costs ^c				
Sick absence costs, \$				
Without hypertension	534.0	487.3	947.5	460.2***
	(521.0 to 547.0)	(475.4 to 499.2)	(885.2 to 1010)	(397.9 to 522.5)
With hypertension	831.3	788.4	1212	423.8***
* *	(790.1 to 872.5)	(746.8 to 829.9)	(1056 to 1368)	(264.3 to 583.3)
Difference ^b	297.3***	301.0***	264.6**	-36.43
	(254.1 to 340.6)	(257.9 to 344.2)	(96.50 to 432.7)	(-207.7 to 134.9)
Observations	139 490	125 345	14 145	139 490
STD costs, \$				
Without hypertension	469.0	402.6	1149	746.0***
v .	(454.6 to 483.3)	(391.2 to 414.1)	(1084 to 1213)	(686.7 to 805.3)
With hypertension	1100	996.9	2156	1160***
•••	(1056 to 1144)	(956.0 to 1038)	(1946 to 2367)	(951.8 to 1367)
Difference ^b	631.0***	594.2***	1008***	413.6***
	(591.4 to 670.7)	(556.9 to 631.6)	(800.3 to 1215)	(205.0 to 622.2)
Observations	1 355 064	1 234 579	120485	1 355 064
LTD costs, \$	1333 001	1201017	120 105	1000001
,	123.8	103.4	328.8	225.4
Without hypertension		103.4	520.0	223.7
Without hypertension		(-150 3 to 357 1)	(-650.8 to 1308)	(-527.9 to 978.7)
•	(-190.4 to 438.1)	(-150.3 to 357.1)	(-650.8 to 1308)	(-527.9 to 978.7) 767 7
With hypertension		(-150.3 to 357.1) 293.5 (-425.3 to 1012)	(-650.8 to 1308) 1061 (-2124 to 4246)	(-527.9 to 978.7) 767.7 (-1787 to 3322)

Table 3. Productivity Losses and Costs Associated With Hypertension, 2021^a

	(-371.5 to 850.1)	(-276.8 to 657.0)	(-1,502 to 2,967)	(-1,294 to 2,379)
Observations	1 331 963	1 211 127	120 836	1 331 963

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** p<0.001, ** p<0.01, * p<0.05

^a A negative binomial model was used for the number of sick absences, STD, and LTD. A generalized linear model for costs associated with sick absences, STD, and LTD. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

^c The productivity costs associated with sick absences, STD, and LTD were obtained by multiplying the number of hours of sick absences, STD, and LTD by the average hourly wage in 2021. Adjustments for absences associated with short-term (70% of hourly wage) and long-term (60% of hourly wage) disability were made. The average hourly wage for all employees on private nonfarm payrolls was derived from the US Bureau of Labor Statistics.

Supplemental Materials eTable 1. The ICD-10-CM for Hypertension and ICD-10-CM, DRG, and ICD-10-PCS Procedure Codes Used for Pregnancy Exclusion

	ICD-10-CM	DRG	ICD-10-PCS
			Procedure
Hypertension	I10-I15	NA	NA
Pregnancy	000-099, 09A1-09A5, Z33, Z34, Z36, Z37, Z3201, Z322, Z39, F53, A34	765, 766, 767, 768, 769, 770, 771, 772, 773, 775, 776, 777, 779, 780, 781, 782	10A0, 10D00Z0, 10D00Z1, 10D00Z2, 10D07Z3, 10D07Z4, 10D07Z5, 10D07Z6, 10D07Z7, 10D07Z8, 10E0XZZ

Abbreviations: CM, clinical modification; DRG, diagnosis-related group; ICD, International Classification of Diseases; NA, not available; PCS, procedure coding system.

eTable 2. Productivity Losses and Costs Associated With Hypertension Using a Zero-Inflated Negative Binomial and a Two-Part Model, 2021^a

	All	Without COVID- 19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Sick absences (days)			0	
Without hypertension	2.163	2.028	3.360	1.332***
	(2.114 to 2.212)	(1.979 to 2.076)	(3.200 to 3.520)	(1.173 to 1.492)
With hypertension	3.180	3.069	4.163	1.094***
	(3.018 to 3.342)	(2.898 to 3.240)	(3.775 to 4.550)	(0.685 to 1.503)
Difference ^b	1.017***	1.041***	0.803***	-0.239
	(0.845 to 1.190)	(0.860 to 1.223)	(0.387 to 1.219)	(-0.676 to 0.199)
Observations	139 490	125 345	14 145	139 490
STD (days)				
Without hypertension	2.958	3.015	2.381	-0.633***
	(2.924 to 2.993)	(2.978 to 3.051)	(2.331 to 2.432)	(-0.691 to -0.576)
With hypertension	3.398	3.424	3.130	-0.293***
	(3.337 to 3.459)	(3.359 to 3.488)	(3.032 to 3.229)	(-0.400 to -0.187)
Difference ^b	0.439***	0.409***	0.749***	0.340***
	(0.375 to 0.504)	(0.340 to 0.478)	(0.641 to 0.857)	(0.219 to 0.461)
Observations	1 355 064	1 234 579	120 485	1 355 064
LTD (days)	1 555 001	1251577	120 105	1555 001
Without hypertension	0.456	0.459	0.427	-0.0318
, in the out of portonision	(0.426 to 0.486)	(0.427 to 0.491)	(0.384 to 0.470)	(-0.0803 to 0.0167)
With hypertension	0.469	0.464	0.514	0.0504
with hypertension	(0.440 to 0.498)	(0.435 to 0.493)	(0.448 to 0.581)	(-0.0155 to 0.116)
Difference ^b	0.0125	0.00508	0.0873*	0.0822*
Difference	(-0.0206 to 0.0456)	(-0.0303 to 0.0404)	(0.0122 to 0.162)	(0.000322 to 0.164)
Observations	1 331 963	1 211 127	120 836	1 331 963
Productivity associated costs ^c				
Sick absence costs, \$				
Without hypertension	533.9	488.1	940.0	451.9***
	(522.0 to 545.9)	(476.6 to 499.6)	(887.8 to 992.2)	(399.4 to 504.5)
With hypertension	826.4	783.6	1205	421.4***
	(788.9 to 863.8)	(745.2 to 822.0)	(1077 to 1333)	(290.0 to 552.9)
Difference ^b	292.4***	295.5***	265.0***	-30.50
	(252.5 to 332.3)	(255.0 to 336.0)	(126.4 to 403.7)	(-172.2 to 111.2)
Observations	139 490	125 345	14 145	139 490
STD costs, \$				
Without hypertension	444.6	390.6	997.6	607.0***
V 1.	(439.2 to 450.0)	(385.3 to 396.0)	(974.4 to 1021)	(583.4 to 630.6)
With hypertension	1014	931.4	1857	926.0***
51		20111		
		(909.7 to 953.1)	(1785 to 1930)	(852.3 to 999.8)
Difference ^b	(992.5 to 1035)	(909.7 to 953.1) 540.8 ***	(1785 to 1930) 859.9 ***	(852.3 to 999.8) 319.1 ***
Difference ^b	(992.5 to 1035) 569.2 ***	540.8***	859.9***	319.1***
	(992.5 to 1035) 569.2*** (546.7 to 591.7)	540.8*** (518.0 to 563.6)	859.9*** (783.3 to 936.4)	319.1*** (241.5 to 396.6)
Observations	(992.5 to 1035) 569.2 ***	540.8***	859.9***	319.1***
Observations LTD costs, \$	(992.5 to 1035) 569.2*** (546.7 to 591.7) 1 355 064	540.8*** (518.0 to 563.6) 1 234 579	859.9*** (783.3 to 936.4) 120 485	319.1*** (241.5 to 396.6) 1 355 064
Observations	(992.5 to 1035) 569.2*** (546.7 to 591.7)	540.8*** (518.0 to 563.6)	859.9*** (783.3 to 936.4)	319.1*** (241.5 to 396.6)

	(121.4 to 144.9)	(111.4 to 135.1)	(189.7 to 275.9)	(65.82 to 153.3)
Difference ^b	80.47***	74.28***	142.5***	68.25**
	(67.74 to 93.19)	(61.58 to 86.98)	(96.45 to 188.6)	(21.88 to 114.6)
Observations	1 331 963	1 211 127	120 836	1 331 963

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** *P* < 0.001, ** *P* < 0.01, * *P* < 0.05

^a This table provides the same dependent variables with Table 3 but with different models for robustness check. A zero-inflated negative binomial model was used for number of sick absences, STD, and LTD. A two-part model was used, where the first part is a logistic regression model, and the second part is a generalized linear model for costs associated with sick absences, STD, and LTD. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

^c The productivity costs associated with sick absences, STD, and LTD were obtained by multiplying the number of hours of sick absences, STD, and LTD by the average hourly wage in 2021. Adjustments for absences associated with short-term (70% of hourly wage) and long-term (60% of hourly wage) disability were made. The average hourly wage for all employees on private nonfarm payrolls was derived from the US Bureau of Labor Statistics.

eTable 3. Supplementary Analysis Using 2020 Data—Total Medical Costs and Health Care Utilization Associated With Hypertension^a

	All	Without COVID- 19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Total medical costs, \$			0	
Without hypertension	9505	8507	28 984	20 477***
	(9042 to 9969)	(8168 to 8847)	(25 901 to 32 068)	(17 698 to 23 256)
With hypertension	18 467	16 583	55 227	38 644***
	(17 573 to 19 360)	(15916 to 17250)	(48 912 to 61 542)	(32 828 to 44 460)
Difference ^b	8961***	8076 ***	26 243***	18 167***
	(8478 to 9445)	(7695 to 8457)	(22 237 to 30 249)	(14 320 to 22 014)
Observations	1 748 789	1 663 548	85 241	1 748 789
Health care utilization	1 /40 /07	1 005 548	85 241	1 /40 /07
Number of emergency department visits				
Without hypertension	0.171	0.157	0.445	0.289***
	(0.170 to 0.172)	(0.156 to 0.158)	(0.437 to 0.454)	(0.280 to 0.297)
With hypertension	0.388	0.365	0.829	0.464***
	(0.384 to 0.392)	(0.361 to 0.370)	(0.799 to 0.859)	(0.434 to 0.494)
Difference ^b	0.217***	0.209***	0.384***	0.175***
	(0.213 to 0.222)	(0.204 to 0.213)	(0.353 to 0.415)	(0.144 to 0.207)
Observations	1 748 789	1 663 548	85 241	1 748 789
Number of inpatient admissions				
Without hypertension	0.0573	0.0337	0.518	0.485***
• •	(0.0515 to 0.0630)	(0.0314 to 0.0360)	(0.442 to 0.594)	(0.410 to 0.559)
With hypertension	0.203	0.131	1.602	1.471***
	(0.184 to 0.222)	(0.123 to 0.140)	(1.368 to 1.837)	(1.244 to 1.698)
Difference ^b	0.146***	0.0978***	1.084***	0.986***
	(0.133 to 0.159)	(0.0915 to 0.104)	(0.918 to 1.250)	(0.825 to 1.147)
Observations	1 748 789	1 663 548	85 241	1 748 789
Number of outpatient visits				
Without hypertension	7.600	7.441	10.70	3.261***
	(7.585 to 7.615)	(7.426 to 7.456)	(10.62 to 10.79)	(3.176 to 3.346)
With hypertension	12.56	12.40	15.64	3.240***
	(12.50 to 12.61)	(12.35 to 12.46)	(15.39 to 15.89)	(2.983 to 3.497)
Difference ^b	4.960***	4.961***	4.940***	-0.0208
	(4.902 to 5.017)	(4.902 to 5.019)	(4.674 to 5.205)	(-0.291 to 0.249)
Observations	1 748 789	1 663 548	85 241	1 748 789
Number of outpatient prescription drugs				
Without hypertension	9.783	9.655	12.28	2.626***
	(9.760 to 9.806)	(9.632 to 9.678)	(12.17 to 12.39)	(2.515 to 2.737)
With hypertension	21.01	20.84	24.31	3.475***
	(20.90 to 21.11)	(20.73 to 20.94)	(23.87 to 24.75)	(3.020 to 3.929)
Difference ^b	11.22***	11.18***	12.03***	0.849***
	(11.12 to 11.33)	(11.07 to 11.29)	(11.57 to 12.49)	(0.382 to 1.316)
Observations	1 748 789	1 663 548	85 241	1 748 789

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** *pP* < 0.001, ** *P* < 0.01, * *P* < 0.05.

^a We used a generalized linear model for total medical costs and a negative binomial model for the number of emergency department visits, outpatient visits, and outpatient prescription drugs. For inpatient admissions, we used a zero-inflated negative binomial model to account for excess zeros. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities. All costs were adjusted to 2021 dollars using the Consumer Price Index from the US Bureau of Labor Statistics.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

eTable 4. Supplementary Analysis Using 2020 Data—Productivity Losses and Costs Associated With Hypertension^a

	All	Without COVID- 19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Sick absences (days)				
Without hypertension	1.843	1.790	2.780	0.990***
	(1.817 to 1.869)	(1.765 to 1.815)	(2.626 to 2.934)	(0.836 to 1.144)
With hypertension	2.704	2.639	3.841	1.202***
	(2.621 to 2.786)	(2.555 to 2.723)	(3.437 to 4.246)	(0.793 to 1.612)
Difference ^b	0.860***	0.849***	1.061***	0.212
	(0.772 to 0.948)	(0.761 to 0.937)	(0.629 to 1.494)	(-0.225 to 0.650)
Observations	222 101	210 181	11 920	222 101
STD (days)				
Without hypertension	2.583	2.367	6.805	4.438***
	(2.485 to 2.682)	(2.290 to 2.444)	(6.073 to 7.537)	(3.750 to 5.126)
With hypertension	6.155	5.801	13.06	7.261***
,, in hypercension	(5.846 to 6.464)	(5.518 to 6.084)	(10.81 to 15.31)	(5.048 to 9.475)
Difference ^b	3.572***	3.434***	6.258***	2.824*
	(3.292 to 3.851)	(3.169 to 3.699)	(4.108 to 8.408)	(0.674 to 4.973)
Observations	1 521 915	1 447 756	74 159	1 521 915
LTD (days)	1 521 715	147750	7+157	1521915
Without hypertension	0.439	0.441	0.397	-0.0447
Without hypertension	(0.412 to 0.466)	(0.413 to 0.469)	(0.335 to 0.459)	(-0.109 to 0.0198)
With hypertension	0.447	0.451	0.378	-0.0734*
with hypertension	(0.405 to 0.490)	(0.407 to 0.495)	(0.316 to 0.440)	(-0.138 to -0.00932)
Difference ^b	· · · · · · · · · · · · · · · · · · ·		, , ,	
Difference	0.00832 (-0.0322 to 0.0488)	0.00976 (-0.0323 to 0.0518)	-0.0190 (-0.103 to 0.0651)	-0.0287 (-0.119 to 0.0620)
Observations	1 470 046	1 396 791	73 255	1 470 046
Productivity associated costs ^c				
Sick absence costs, \$				
Without hypertension	453.2	440.1	684.8	244.7***
	(445.3 to 461.1)	(432.4 to 447.8)	(637.1 to 732.4)	(197.0 to 292.4)
With hypertension	665.1	649.2	946.1	296.9***
	(639.5 to 690.7)	(623.4 to 675.0)	(820.0 to 1,072)	(169.3 to 424.6)
Difference ^b	211.9***	209.1***	261.3***	52.25
	(184.7 to 239.0)	(181.8 to 236.3)	(126.4 to 396.2)	(-83.98 to 188.5)
Observations	222 101	210 181	11 920	222 101
STD costs, \$				
Without hypertension	444.7	407.5	1172	764.2***
51	(432.2 to 457.3)	(397.8 to 417.2)	(1079 to 1265)	(677.0 to 851.4)
With hypertension	1060	998.7	2249	1251***
	(1020 to 1099)	(962.9 to 1035)	(1964 to 2535)	(969.9 to 1531)
Difference ^b	614.9***	591.2***	1078***	486.3***
	(579.6 to 650.3)	(557.7 to 624.8)	(805.0 to 1350)	(213.9 to 758.7)
Observations	1 521 915	1 447 756	74 159	1 521 915
LTD costs, \$				
Without hypertension	97.21	90.79	219.7	128.9
	(-36.18 to 230.6)	(-29.58 to 211.2)	(-213.0 to 652.4)	(-205.8 to 463.6)
With hypertension	281.2	263.3	622.6	359.4

	(-102.9 to 665.2)	(-84.64 to 611.1)	(-677.6 to 1923)	(-686.2 to 1405)
Difference ^b	184.0	172.5	403.0	230.5
	(-70.17 to 438.1)	(-58.48 to 403.4)	(-528.1 to 1334)	(-556.1 to 1017)
Observationss	1 470 046	1 396 791	73 255	1 470 046

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** *Pp* < 0.001, ** *P* < 0.01, * *P* < 0.05.

^a A negative binomial model was used for the number of sick absences and STD. For number of LTD, we used a zero-inflated negative binomial model. A generalized linear model for costs associated with sick absences, STD, and LTD. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities. All costs were adjusted to 2021 dollars using the Consumer Price Index from the US Bureau of Labor Statistics.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

^c The productivity costs associated with sick absences, STD, and LTD were obtained by multiplying the number of hours of sick absences, STD, and LTD by the average hourly wage in 2020. Adjustments for absences associated with short-term (70% of hourly wage) and long-term (60% of hourly wage) disability were made. The average hourly wage for all employees on private nonfarm payrolls was derived from the US Bureau of Labor Statistics.